Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer.
This study was conducted to evaluate the significance of circulating free DNA (CFDNA), p53 antibody (p53-Ab) and mutations of KRAS gene in the development of endometrial cancer (EC). A total of 109 patients with EC (87 patients with Type I and 22 patients with Type II) took part in this study. KRAS mutations and CFDNA were detected by means of the PCR-RFLP and enriched by the PCR-RFPL method. ELISA was used to analyze plasma p53-Ab. Tissue expression of P53 protein was evaluated immunohistochemically (IHC). The frequency of KRAS mutations was especially high in Grade 2 of Type I EC. CFDNA was frequently detected in patients with early stage of Type II EC at a low level of grade. It is noteworthy that the p53-Ab positive rate increased in the higher grade of Type I tumors. A significant difference in the number of cases with the p53-Ab was found in the advanced stage of Type I tumors. The frequency of KRAS and p53-Ab correlates with tumor stage only in the Type I EC. Plasma CFDNA and p53-Ab offer a chance to develop a procedure for EC Type II diagnosis. The association between tumor cells related to CFDNA and p53-Ab with Type II tumor suggests that it might potentially serve as a marker in predicting the prognosis and offers a possibility to individualize treatment regimen.
Dobrzycka
Bozena
B
Department of Obstetrics and Gynecology, Medical University of Bialystok, Bialystok, Poland.
Terlikowski
Slawomir J
SJ
Mazurek
Andrzej
A
Kowalczuk
Oksana
O
Niklinska
Wieslawa
W
Chyczewski
Lech
L
Kulikowski
Marek
M
D000368:Aged; D000906:Antibodies / Q000097:blood; D001483:Base Sequence; D004247:DNA / Q000097:blood*; D017931:DNA Primers; D016889:Endometrial Neoplasms / Q000097:blood / Q000235:genetics* / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D011905:Genes, ras; D006801:Humans; D008875:Middle Aged; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
D000906:Antibodies; D017931:DNA Primers; D016159:Tumor Suppressor Protein p53; D004247:DNA